# Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine

> **NCT02014168** · PHASE1 · TERMINATED · sponsor: **University of Oxford** · enrollment: 3 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Viroflu® and MVA-NP+M1
- **BIOLOGICAL:** Viroflu® and saline placebo

## Key facts

- **NCT ID:** NCT02014168
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Futility
- **Last updated:** 2014-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02014168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02014168, "Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02014168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*